Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics (Q45893946)
Jump to navigation
Jump to search
scientific article published on 4 November 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics |
scientific article published on 4 November 2015 |
Statements
1 reference
Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics (English)
1 reference
Thomas F Gajewski
1 reference
Christopher Harvey
1 reference
Kutlu Elpek
1 reference
Ellen Duong
1 reference
Tyler Simpson
1 reference
ChengYi J Shu
1 reference
Lindsey Shallberg
1 reference
Matthew Wallace
1 reference
Sriram Sathyanarayanan
1 reference
Robert Mabry
1 reference
Michael Briskin
1 reference
Jennifer Michaelson
1 reference
4 November 2015
1 reference
1 reference
3
1 reference
O9-O9
1 reference
Suppl 2
1 reference
Identifiers
1 reference
1 reference